Type 1 ROP or death before determination of ROP outcome using the adjudicated ROP outcome · preterm infants with or at risk of respiratory distress syndrome
Inositol supplementation IV initially followed by enteral… showed no clear difference in type 1 ROP or death before determination of ROP outcome using the… compared with placebo (moderate certainty).
1 finding from 1 review
Type 1 ROP including adjudicated ROP outcome · preterm infants with or at risk of respiratory distress syndrome
Inositol supplementation IV initially followed by enteral… showed no clear difference in type 1 ROP including adjudicated ROP outcome compared with placebo (moderate certainty).
1 finding from 1 review
Bleeding: Number of days on which a significant bleeding event occurred3 · People with a haematological disorder
Time to first pulmonary exacerbation · adults and children with cystic fibrosis
1 finding from 1 review
Chronic lung disease · preterm infants (< 37 weeks GA) at risk of chronic lung disease
Summary of findings table ‐ Salbutamol showed no clear difference in chronic lung disease at 28 days compared with placebo (low certainty).
1 finding from 1 review
Maternal readmission within 28 days · childbearing women and their infants (all) (important/secondary outcomes)
It is very uncertain whether summary of findings table ‐ Midwife continuity models changes maternal readmission within 28 days compared with other models of care (very low certainty).
1 finding from 1 review
Neonatal readmission within 28 days · childbearing women and their infants (all) (important/secondary outcomes)
1 finding from 1 review
Neonatal death (baby born alive at any gestation and dies within 28 days) · childbearing women and their infants (all) (important/secondary outcomes)
It is very uncertain whether summary of findings table ‐ Midwife continuity of care models changes neonatal death (baby born alive at any gestation and dies within 28… compared with other models of care (very low certainty).
1 finding from 1 review
Mortality within the longest · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with cardiopulmonary bypass
Prophylactic corticosteroids showed no clear difference in all‐cause mortality (during the index hospital admission, or within… compared with placebo or no corticosteroids (low certainty).
1 finding from 1 review
Length of stay · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with cardiopulmonary bypass
1 finding from 1 review
Time to complete healing · adults with surgical wounds
The review found no eligible studies for this question.
1 finding from 1 review
Time to complete healing · adults with surgical wounds
1 finding from 1 review
Time to complete healing · adults with surgical wounds
1 finding from 1 review
Time to complete healing · adults with surgical wounds
The review found no eligible studies for this question.
1 finding from 1 review
Time to complete healing · adults with surgical wounds
The review found no eligible studies for this question.
1 finding from 1 review
Frequency of cocaine use (mean number of days or weeks of cocaine use at the end of treatment) · patients with the treatment of cocaine dependence
1 finding from 1 review
Frequency of cocaine use (mean number of days or weeks of cocaine use at the end of treatment) · patients with the treatment of cocaine dependence
1 finding from 1 review
All‐cause mortality at 28 days and before discharge from hospital · preterm born neonates
1 finding from 1 review
Infectious complications · people undergoing gastrointestinal surgery
Immune‐enhancing supplements (oral or enteral) showed no clear difference in infectious complications recorded up to 30 days postdischarge compared with usual care or control (low certainty).
1 finding from 1 review
Length of hospital stay · people undergoing gastrointestinal surgery
1 finding from 1 review